Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01045551Phase 2Completed

Open Label Pilot Study of Apremilast in Treatment of Rosacea

Role: lead

NCT00986427Phase 2Completed

Restasis for Treatment of Brittle Nails

Role: lead

NCT01314495Phase 2Withdrawn

Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis

Role: lead

All 3 trials loaded